Human B7-2/CD86 Antibody

Catalog #: MAB108522 Datasheet / COA / SDS

Catalog #	Availability	Size / Price	Qty
MAB108522-100
MAB108522-SP

CTLA-4/Fc-tag Binding to B7-2 is Blocked by Human B7-2/CD86 Antibody.

1 Image

All B7-2/CD86 Antibodies

Product Details

Supplemental Products

Reviews

Summary Data Examples Preparation and Storage Reconstitution Calculator Background Product Datasheets Related Research Areas

Human B7-2/CD86 Antibody Summary

Species Reactivity

Human

Specificity

Detects human B7-2/CD86 in direct ELISAs.

Source

Monoclonal Mouse IgG₁ Clone # 1036411

Purification

Protein A or G purified from hybridoma culture supernatant

Immunogen

Human embryonic kidney cell, HEK293 derived human B7-2/CD86
Leu26-Pro247
Accession # NP_787058

Formulation

Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.

Label

Unconjugated

Applications

Recommended Concentration

Sample

Neutralization

In a functional ELISA binding assay, 15.0-150 ng/mL of this antibody will block 50% of the binding of 200 ng/mL of recombinant human CTLA-4/Fc (Catalog # 7868-CT) to immobilized recombinant human B7-2/His (Catalog # 9090-B2) coated at 0.5 μg/mL (100 µL/well). At 1.0 μg/mL, this antibody will block >90% of the binding.

Please Note: Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website.

Scientific Data

Neutralization

View Larger

CTLA-4/Fc-tag Binding to B7-2 is Blocked by Human B7-2/CD86 Antibody. In a functional ELISA binding assay, 15.0-150 ng/mL of this antibody will block 50% of the binding of 200 ng/mL of recombinant human CTLA-4/Fc (7868-CT) to immobilized recombinant human B7-2/His (9090-B2) coated at 0.5 μg/mL (100 µL/well). At 1.0 μg/mL, this antibody will block >90% of the binding.

Reconstitution Calculator

Preparation and Storage

Reconstitution

Reconstitute at 0.5 mg/mL in sterile PBS.

Shipping

The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below. *Small pack size (SP) is shipped with polar packs. Upon receipt, store it immediately at -20 to -70 °C

Stability & Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles.

12 months from date of receipt, -20 to -70 °C as supplied.
1 month, 2 to 8 °C under sterile conditions after reconstitution.
6 months, -20 to -70 °C under sterile conditions after reconstitution.

Background: B7-2/CD86

B7-2, also known as CD86, B70, and ETC-1, is a 60-100 kDa variably glycosylated protein in the B7 family. B7 family members are transmembrane cell surface molecules that play important roles in immune activation and the maintenance of immune tolerance (1, 2). Mature human B7-2 consists of a 224 amino acid (aa) extracellular domain (ECD) with two Ig-like domains, a 21 aa transmembrane segment, and a 61 aa cytoplasmic tail (3, 4). Within the ECD, human B7-2 shares 59% aa sequence identity with mouse and rat B7-2. Alternative splicing of human B7-2 generates additional isoforms that lack both Ig-like domains or a region that includes the transmembrane segment. B7-2 is highly expressed on activated antigen presenting cells (APC), e.g. B cells, dendritic cells, and monocytes (4-7), as well as on vascular endothelial cells (8). B7-2 and the closely related B7-1/CD80 exhibit overlapping but distinct functional properties. Their binding to CD28, which is constitutively expressed on T cells, enhances T cell receptor signaling and also provides TCR-independent co-stimulation (3-5, 7, 9-11). B7-1 and B7-2 additionally bind the CD28-related protein, CTLA-4, which is up-regulated and recruited to the immunological synapse (IS) at the onset of T cell activation (3-5, 7, 9, 10). CTLA-4 ligation inhibits the T cell response and supports regulatory T cell function (12). B7-2 is expressed earlier than B7-1 following APC activation (6), and both proteins bind with higher affinity to CTLA-4 than to CD28 (10). B7-2 promotes the stabilization of CD28 in the IS, while B7-1 is primarily responsible for promoting CTLA-4 recruitment and accumulation in the IS (13). The relative participation of B7-1 and B7-2 in T cell co-stimulation can also alter the Th1/Th2 bias of the immune response (14). Both B7-1 and B7-2 serve as cellular receptors for B species adenoviruses (15).

References

Greenwald, R.J. et al. (2005) Annu. Rev. Immunol. 23:515.
Bour-Jordan, H. et al. (2011) Immunol. Rev. 241:180.
Freeman, G.J. et al. (1993) Science 262:909.
Azuma, M. et al. (1993) Nature 366:76.
Freeman, G.J. et al. (1993) J. Exp. Med. 178:2185.
Lenschow, D.J. et al. (1993) Proc. Natl. Acad. Sci. USA 90:11054.
Hathcock, K.S. et al. (1993) Science 262:905.
Seino, K. et al. (1995) Int. Immunol. 7:1331.
Chen, C. et al. (1994) J. Immunol. 152:4929.
Lanier, L.L. et al. (1995) J. Immunol. 154:97.
Rudd, C.E. et al. (2009) Immunol. Rev. 229:12.
Wing, K. et al. (2011) Trends Immunol. 32:428.
Pentcheva-Hoang, T. et al. (2004) Immunity 21:401.
Kuchroo, V.K. et al. (1995) Cell 80:707.
Short, J.J. et al. (2006) Virus Res. 122:144.

Entrez Gene IDs

942 (Human); 12524 (Mouse); 56822 (Rat); 102147235 (Cynomolgus Monkey)

Alternate Names

Activation B7-2 antigen; B70; B7-2 antigen; B72; B7-2; B-lymphocyte activation antigen B7-2; BU63; CD28 antigen ligand 2; CD28LG2B7-2 antigen); CD86 antigen; CD86 molecule; CD86; CTLA-4 counter-receptor B7.2; FUN-1; LAB72; MGC34413; T-lymphocyte activation antigen CD86